secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immix Biopharma, Inc. (IMMX)
CIK:        0001873835
Form:       8-K
Filed at:   2022-01-19T23:59:59+00:00
Accession:  0001493152-22-001557
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immix Biopharma announces positive interim safety data: 100% IMX-110 treatment cycle completion in Phase 1b/2a trial
--------------------------------------------------------------------------------

- 100% of patients completed planned treatment cycles with IMX-110 without drug-related interruptions in ongoing Phase 1b/2a trial.
- Historical comparators for approved soft tissue sarcoma drugs show 43-67% completion rates (Demetri et al., 2015; Schöffski et al., 2016).
- IMX-110 has FDA Orphan Drug Designation for soft tissue sarcoma and Rare Pediatric Disease Designation for rhabdomyosarcoma.
- Immix Biopharma (NASDAQ: IMMX) is developing IMX-110 as monotherapy for soft tissue sarcoma, a $3B market targeting $6.5B by 2030.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873835/000149315222001557/0001493152-22-001557-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873835/000149315222001557/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-001557

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer